AXITINIB
| Brand name | INLYTA |
|---|---|
| Active ingredient | AXITINIB |
| Strength | 5MG |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | January 2012 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 10869924*PED | July 2037 | — |
| 10869924 | January 2037 | use U-3044 |
| 12534530*PED | August 2035 | — |
| 10570202*PED | August 2035 | — |
| 12534530 | February 2035 | use U-4412 |
| 10570202 | February 2035 | use U-2844 |
| 8791140*PED | June 2031 | — |
| 8791140 | December 2030 | substance |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.